The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The Blood Screening Market encompasses a range of diagnostic procedures used to test donated blood for infections, diseases, and other health conditions before it is used for transfusions or other medical purposes. This market plays a critical role in ensuring the safety of blood supplies and preventing the transmission of infections such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible diseases. Driven by increasing demand for safe blood, rising awareness about blood-related disorders, and advancements in screening technologies such as nucleic acid testing and immunoassays, the Blood Screening Market continues to expand. Government initiatives, stringent regulations, and the growing need for early disease detection further contribute to the growth of this essential healthcare sector.

Continue reading for more details:

https://www.fortunebusinessinsights.com/blood-screening-market-102552

Market Segmentation

• By Technology: The Blood Screening Market is divided into immunoassays, nucleic acid testing (NAT), serological tests, and rapid diagnostic tests.
• By Application: Screening for infectious diseases, cancer biomarkers, genetic disorders, and anemia contribute diverse segments within the Blood Screening Market.
• By End‑User: Hospital labs, diagnostic centers, blood banks, and reference laboratories each capture distinct portions of the Blood Screening Market.
• By Sample Type: The Blood Screening Market includes whole blood, serum, plasma, and point-of-care sample formats.

List Of Key Companies Profiled:

• Bio-Rad Laboratories, Inc.
• Grifols, S.A.
• Hoffmann-La Roche
• Ortho Clinical Diagnostics
• BD
• DiaSorin S.p.A.
• Thermo Fisher Scientific Inc.
• Abbott
• QUOTIENT